This is the first report from a randomized, placebo-controlled trial of tamoxifen for the chemoprevention of breast cancer in women deemed to be at high risk.
In June a report emerged in the American Journal of Obstetrics and Gynecology that should get every obstetrical providers attention.
Øjvind Lidegaard is an obstetrician-gynecologist in Denmark who has become an epidemiologist. His case-control studies using the Denmark Registry are recognized as being as good as can be. Lidegaard and colleagues have now published 5-year case-control studies of OCs and venous thromboembolism, and cerebral thrombosis.
Cervical cancer is the third most common gynecologic malignancy in the United States, accounting for approximately 13,000 new cases in 2002. In this country, the major issue responsible for disparate practice patterns is one of specialty territoriality.
